In the field of tumor, Hengrui and CStone reached a strategic cooperation of 1.3 billion yuan

Recently, Hengrui Pharmaceuticals and CStone Pharmaceuticals jointly announced that the two parties have reached a strategic cooperation and exclusive license agreement in the Greater China region for the anti-CTLA-4 monoclonal antibody CS1002
.
According to the agreement, Hengrui Pharmaceuticals will pay CStone Pharmaceuticals a total of approximately US$200 million (approximately 1.
3 billion yuan) in advance and milestone payments, as well as royalties that are a double-digit percentage of annual net sales after the products are launched
.
CStone Pharmaceuticals will grant Hengrui Medicine the exclusive right to develop, register, produce and commercialize the anti-CTLA-4 monoclonal antibody CS1002 in the Greater China region.
The permitted use is for all human and animal diseases
.
At the same time, CStone Pharmaceuticals will also retain the right to develop and commercialize the anti-CTLA-4 monoclonal antibody CS1002 outside of Greater China
.
According to the data, CStone Pharmaceuticals is a biopharmaceutical company focusing on research, development and commercialization of innovative tumor immunotherapy and precision treatment drugs to meet the medical needs of cancer patients in China and the world.
Its core is the combination of tumor immunotherapy and has established A rich product pipeline consisting of 15 tumor drug candidates has been established
.
Among them, CS1002 is a fully human anti-CTLA-4 monoclonal antibody independently developed by CStone Pharmaceuticals
.
Although it is currently in the clinical development stage, the industry believes that CS1002 will become an important supplement to Hengrui Pharmaceutical's oncology product pipeline layout, with greater potential for combination medications, and will further enrich Hengrui Pharmaceutical's product portfolio and strengthen its ability to serve patients
.
As we all know, Hengrui Medicine made its fortune with generic drugs
.
However, the sales of its traditional generic drugs began to decline due to the impact of national and local volume purchases
.
According to Hengrui Pharmaceutical’s “2021 Semi-Annual Report”, since 2018, Hengrui Pharmaceuticals has entered the country for centralized procurement of a large number of drugs, which has caused greater pressure on its performance, and Hengrui Pharmaceutical’s innovative drug research and development has begun to accelerate
.
Among them, the field of oncology drugs is its focus on innovative research and development..
It is understood that with years of continuous and high-intensity investment in innovation, Hengrui currently has a rich R&D pipeline in the oncology field, including carrelizumab, apatinib mesylate, pyrrotinib maleate, Heavy anti-tumor drugs such as fluzoparil cover multiple indications such as lymphoma, liver cancer, lung cancer, esophageal cancer, nasopharyngeal cancer, and ovarian cancer
.
It is worth mentioning that in 2020, its anti-tumor product revenue has reached 15.
268 billion yuan
.
It is worth noting that in the field of non-tumor, Hengrui Medicine has also achieved the expertise in autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, infectious diseases, respiratory diseases, blood diseases, neurological diseases, ophthalmology and other fields.
Extensive coverage
.
In addition, Hengrui Pharmaceuticals is also conducting "full excavation" in the R&D pipeline, including the exploration of the indication potential of drugs under research "from inside to outside", and the layout of products with different mechanism types "from front to back" in the disease field
.
In general, Hengrui Medicine's current R&D pipeline is very rich, multifaceted and in-depth
.
Behind this, in fact, every research and every attempt is inseparable from a large amount of capital investment
.
In the future, the industry predicts that Hengrui Pharmaceuticals will bring more innovative results under the continuous increase of R&D investment
.